Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease(2020)10.1016/j.bbadis.2020.165962Source: DataRank Database

Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma is a research paper published in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020). On theSindex it has a DataRank of 0. It has been cited 48 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access48 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.05)OA: bronzeTopics (61)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Lin Zhao ORCID,Diana Whitaker‐Menezes ORCID,Tingting Zhan ORCID,Károly Szuhai ORCID,Judith V.M.G. Bovée ORCID

Live enrichment

PubMed:32920118 PMC:PMC7680391 OpenAlex:https://openalex.org/W3085059698

NCI NIH HHS

Grant: R37 CA234239

NCI NIH HHS

Grant: P30 CA056036

National Institutes of Health

Grant: 5R37CA234239-02

Tumor Microenvironment Metabolism in Invasive Ductal Carcinoma of the Breast

National Institutes of Health

Grant: 3P30CA056036-22S1

Strengthening Community Engagement in Colorectal Cancer Screening and Clinical Trial Enrollment Through a Community Health Educator

National Institutes of Health

FWCI

5.05

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttps://www.sciencedirect.com/science/article/pii/S0925443920303100/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0925443920303100/pdf

journalhttps://doi.org/10.1016/j.bbadis.2020.165962

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32920118

journalhttps://jdc.jefferson.edu/medoncfp/121

Fields of Study

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and TreatmentCancer-related molecular mechanisms research0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Mitochondrial Precursor Protein Import Complex ProteinsAnimalsAntineoplastic AgentsBone NeoplasmsChondrosarcomaDrug Screening Assays, AntitumorFemaleHumansMaleMice, NudeNeoplasms, ExperimentalReceptors, Cell SurfaceTumor Cells, CulturedApoptosisDrug Resistance, NeoplasmMembrane Transport ProteinsCell ProliferationMitochondrial MembranesMice

Keywords

ChondrosarcomaCancer researchBiologyChemotherapySarcomaCancer cellCancerPrimary boneMalignancyPathologyMedicineGeneticsMitochondriaApoptosisProliferationChemotherapy ResistanceMale610Mice, NudeAntineoplastic AgentsBone NeoplasmsReceptors, Cell SurfaceMiceMitochondrial Precursor Protein Import Complex ProteinsMedicine and Health SciencesTumor Cells, CulturedAnimalsHumansCell ProliferationMembrane Transport ProteinsNeoplasms, ExperimentalOncologyDrug Resistance, NeoplasmMitochondrial MembranesFemaleDrug Screening Assays, Antitumor

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930306.v1figshare

Additional file 1 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930306figshare

Additional file 2 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930309.v1figshare

Additional file 2 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930309figshare

Additional file 3 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930312.v1figshare

Additional file 3 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930312figshare

Additional file 4 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930315.v1figshare

Additional file 4 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930315figshare

Additional file 5 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930318.v1figshare

Additional file 5 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930318figshare

Additional file 6 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930321.v1figshare

Additional file 6 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930321figshare

Additional file 7 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930324.v1figshare

Additional file 7 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930324figshare

Additional file 8 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930327figshare

Additional file 8 of AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

10.6084/m9.figshare.23930327.v1figshare

Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma

FAIR Checklist

Authors (10)

Funding (5 grants)

Impact

Open Access

Topics

Linked Datasets (16)

Annotations (Europe PMC)